A career at AbbVie As one company, our ~50,000 employees around the world focus on discovering and delivering transformational medicines and products. search open jobs

2020年5月8日 · AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all...

AbbVie focused more on therapeutics in immunology, hematologic oncology and other specialty areas, while Allergan focused on aesthetics, eye care, women’s health and neuroscience. This made our companies – from a portfolio perspective – very different.

Simplifying the process for tracking, initiating warranty claims, and submitting product quality complaints or adverse events for select AbbVie products – including Eye care products marketed as Allergan, an AbbVie company and our Allergan Aesthetics portfolio.

Appendix I to the Rule 2.5 announcement issued jointly by AbbVie and Allergan on June 25, 2019 (the “Rule 2.5 Announcement”) contains further details of the sources of information and bases of calculations set out in this presentation.

2024年10月24日 · Allergan Aesthetics, an AbbVie company, develops, manufactures and markets a portfolio of leading aesthetics brands and products. Be part of the team that believes in the power of confidence.

2024年10月24日 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives

LO LOESTRIN FE® and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company. LUMIGAN® bimatoprost ophthalmic solution

Allergan Aesthetics will operate as a new global dedicated business with its own research and development function under the AbbVie umbrella and will include leading aesthetic products including, BOTOX Cosmetic, the JUVEDERM collection of dermal fillers and COOLSCULPTING body contouring,

2024年3月6日 · The presented data across AbbVie and Allergan Aesthetics' extensive portfolios reinforce the companies' ongoing commitment to developing transformative medical dermatology and aesthetic treatments to advance and redefine the standard of care for patients.